Pharming receives EMA approval of new facility for expansion of RUCONEST® production (2019)

Highlights: New production facility will significantly increase production capacity of RUCONEST® Product manufactured at the new facility during the approval process is now available for distribution within the EU As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce the approval of our new facility, which will enable us to significantly increase production capacity for supply to patients in the EU — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗